52417-09-1

Basic information

• Product Name: 3'-O-(4,4'-dimethoxytriphenylmethyl)-5'-O-fluorenylmethoxycarbonylthymidine
• Synonyms: 3'-O-(4,4'-dimethoxytriphenylmethyl)-5'-O-fluorenylmethoxycarbonylthymidine
• CAS NO: 52417-09-1
• Molecular Weight: 846.977
• Mol File: 52417-09-1.mol
• Article Data: 37

Chemical Properties

• CAS DataBase Reference: 3'-O-(4,4'-dimethoxytriphenylmethyl)-5'-O-fluorenylmethoxycarbonylthymidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-O-(4,4'-dimethoxytriphenylmethyl)-5'-O-fluorenylmethoxycarbonylthymidine(52417-09-1)
• EPA Substance Registry System: 3'-O-(4,4'-dimethoxytriphenylmethyl)-5'-O-fluorenylmethoxycarbonylthymidine(52417-09-1)

Safety Data

• Hazardous Substances Data: 52417-09-1(Hazardous Substances Data)

Upstream product

• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 50-89-5 thymidine 
• 288-36-8 1,2,3-triazole 
• 126144-60-3 3'-O-trimethylsilyl-5'-O-dimethoxytrityl-thymidine 
• 108-10-1 4-methyl-2-pentanone 
• 50-89-5 C₁₀H₁₄N₂O₅ 

Relevant articles and documents

Efficient large-scale synthesis of 5′-O-dimethoxytrityl-N 4-benzoyl-5-methyl-2′-deoxycytidine

An efficient process to synthesize 5′- O -dimethoxytrityl-N 4 -benzoyl-5-methyl-2 ′-deoxycytidine in high yield and quality is described. Final benzoylation was improved by developing a method to selectively hydrolyze benzoyl ester impurities. This inexpensive approach was scaled up to multi-kilogram quantities for routine use in oligonucleotide therapeutics. Copyright Taylor & Francis Group, LLC.

Antisense inhibition via RNAse H-independent reduction in mRNA

The present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.

Antisense modulation of phosphotyrosyl phosphatase activator expression

Antisense compounds, compositions and methods are provided for modulating the expression of phosphotyrosyl phosphatase activator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphotyrosyl phosphatase activator. Methods of using these compounds for modulation of phosphotyrosyl phosphatase activator expression and for treatment of diseases associated with expression of phosphotyrosyl phosphatase activator are provided.